Stockscreener 앱 받기
12.56
2.41%
-0.31
시간 외 거래:
12.56
전일 마감가:
$12.87
열려 있는:
$12.57
하루 거래량:
131.59K
Relative Volume:
0.57
시가총액:
$471.00M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.16%
1개월 성능:
+30.56%
6개월 성능:
-42.75%
1년 성능:
+0.00%
1일 변동 폭
$12.33
$13.06
1주일 범위
$12.33
$13.56
52주 변동 폭
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
명칭
Oruka Therapeutics Inc
전화
650-606-7910
주소
855 OAK GROVE AVE., MENLO PARK
ORKA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
12.56 | 471.00M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-22 | 개시 | BTIG Research | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-10-11 | 개시 | Stifel | Buy |
| 2024-10-07 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | Leerink Partners | Outperform |
| 2024-09-16 | 개시 | TD Cowen | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2018-02-27 | 개시 | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 개시 | Dawson James | Buy |
모두보기
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
Wall Street Zen Downgrades Oruka Therapeutics (NASDAQ:ORKA) to Sell - Defense World
Millennium Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Squarepoint Ops LLC Acquires New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial - MSN
Oruka Therapeutics Holds Annual Stockholders Meeting - TipRanks
Jane Street Group LLC Buys New Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
HC Wainwright Has Positive Estimate for ORKA Q2 Earnings - Defense World
Northern Trust Corp Acquires Shares of 64,044 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
H.C. Wainwright maintains Buy on Oruka stock, $45 target By Investing.com - Investing.com India
H.C. Wainwright maintains Buy on Oruka stock, $45 target - Investing.com UK
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Upgraded at BTIG Research - Defense World
BTIG Initiates Oruka Therapeutics at Buy With $44 Price Target - marketscreener.com
BTIG sets $44 price target on Oruka Therapeutics stock - Investing.com UK
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Oruka Therapeutics begins trial for psoriasis treatment By Investing.com - Investing.com South Africa
Oruka Therapeutics begins trial for psoriasis treatment - Investing.com Australia
Oruka Therapeutics Begins Dosing in Phase 1 Trial of ORKA-002 for Skin Disease Treatment - marketscreener.com
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody - GlobeNewswire
Revolutionary Psoriasis Treatment Begins Human Trials: Only 2-3 Doses Per Year Needed - Stock Titan
Wedbush Forecasts Reduced Earnings for Oruka Therapeutics - Defense World
What is Wedbush’s Estimate for ORKA FY2029 Earnings? - Defense World
Wedbush Reaffirms “Outperform” Rating for Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics (NASDAQ:ORKA) versus Trinity Biotech (NASDAQ:TRIB) Critical Analysis - Defense World
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Oruka Therapeutics Announces Accelerated Clinical Timelines and Strong Financial Position for Psoriasis Programs - Nasdaq
Oruka Therapeutics Reports First Quarter 2025 Financial Results And Provides Corporate Update - marketscreener.com
Oruka Therapeutics, Inc. SEC 10-Q Report - TradingView
Oruka Therapeutics (NASDAQ:ORKA) and Trinity Biotech (NASDAQ:TRIB) Head-To-Head Analysis - Defense World
JPMorgan Chase & Co. Acquires New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Barclays PLC Purchases Shares of 74,583 Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
HC Wainwright Issues Negative Estimate for ORKA Earnings - Defense World
Equities Analysts Offer Predictions for ORKA Q1 Earnings - Defense World
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference - GlobeNewswire
Geode Capital Management LLC Boosts Stock Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Comparing TNF Pharmaceuticals (NASDAQ:TNFA) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Oruka Therapeutics Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Oruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on Thursday - Defense World
Vanguard Group Inc. Purchases 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) - The AM Reporter
Vanguard Group Inc. Acquires 1,572,853 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Acquired by Wellington Management Group LLP - Defense World
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Charles Schwab Investment Management Inc. Takes Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Contrasting Achieve Life Sciences (NASDAQ:ACHV) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Fairmount Funds Management LLC Increases Stake in Oruka Therapeu - GuruFocus
Oruka Therapeutics Reports Strong 2024 Financial Results - TipRanks
Oruka Therapeutics Inc (ORKA) 재무 분석
Oruka Therapeutics Inc (ORKA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):